Prima BioMed (NASDAQ:IMMP) Stock Crosses Below 50-Day Moving Average – Should You Sell?

Prima BioMed Ltd (NASDAQ:IMMP)’s share price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.42 and traded as low as $0.3815. Prima BioMed shares last traded at $0.3889, with a volume of 310,698 shares changing hands.

Analyst Upgrades and Downgrades

IMMP has been the subject of several research reports. Wall Street Zen raised Prima BioMed to a “hold” rating in a research report on Saturday, April 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Prima BioMed in a research report on Friday, July 10th. Finally, Maxim Group raised Prima BioMed from a “hold” rating to a “buy” rating in a research note on Wednesday, June 17th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $5.50.

Prima BioMed Stock Performance

The business’s 50-day moving average is $0.42 and its 200-day moving average is $1.28.

Hedge Funds Weigh In On Prima BioMed

An institutional investor recently raised its stake in Prima BioMed stock. Jane Street Group LLC grew its holdings in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. 2.32% of the stock is currently owned by institutional investors.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.